

# Juergen Wasem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2228430/publications.pdf>

Version: 2024-02-01

23  
papers

1,652  
citations

471509

17  
h-index

677142

22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. <i>Health Policy</i> , 2022, 126, 49-59.	3.0	7
2	Problems and Barriers Related to the Use of Digital Health Applications: Protocol for a Scoping Review. <i>JMIR Research Protocols</i> , 2022, 11, e32702.	1.0	4
3	A complex intervention to promote prevention of delirium in older adults by targeting caregiverâ€™s participation during and after hospital discharge â€“ study protocol of the TRANsport and DELirium in older people (TRADE) project. <i>BMC Geriatrics</i> , 2021, 21, 646.	2.7	5
4	Health Insurance Plans and Programs: An Overview. , 2017, , 418-427.		6
5	Global Risk-Adjusted Payment Models. , 2016, , 311-362.		6
6	High cost pool or high cost groupsâ€™How to handle high(est) cost cases in a risk adjustment mechanism?. <i>Health Policy</i> , 2016, 120, 141-147.	3.0	20
7	Demand-side strategies to deal with moral hazard in public insurance for long-term care. <i>Journal of Health Services Research and Policy</i> , 2015, 20, 170-176.	1.7	17
8	Childhood Psoriasisâ€™An Analysis of German Health Insurance Data. <i>Pediatric Dermatology</i> , 2014, 31, 8-13.	0.9	37
9	Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 972-979.	1.8	12
10	Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60Âyears: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2014, 93, 1279-1286.	1.8	83
11	The new risk adjustment formula in Germany: Implementation and first experiences. <i>Health Policy</i> , 2013, 109, 253-262.	3.0	50
12	Preconditions for efficiency and affordability in competitive healthcare markets: Are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland?. <i>Health Policy</i> , 2013, 109, 226-245.	3.0	113
13	Economic Evaluation of Treatment Options in Patients with Alzheimerâ€™s Disease. <i>Drugs</i> , 2012, 72, 789-802.	10.9	63
14	Heart Failure. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2009, 106, 269-75.	0.9	145
15	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. <i>Value in Health</i> , 2008, 11, 539-544.	0.3	138
16	Risk adjustment and risk selection in Europe: 6 years later. <i>Health Policy</i> , 2007, 83, 162-179.	3.0	98
17	Evaluation of prevention: A challenge for economists. <i>International Journal of Public Health</i> , 2007, 52, 337-338.	2.6	0
18	Neonatal hearing screening: modelling cost and effectiveness of hospital- and community-based screening. <i>BMC Health Services Research</i> , 2006, 6, 14.	2.2	26

#	ARTICLE	IF	CITATIONS
19	Consumer price sensitivity and social health insurer choice in Germany and The Netherlands. International Journal of Health Care Finance and Economics, 2003, 3, 117-138.	1.2	92
20	Needs for further improvement: risk adjustment in the German health insurance system. Health Policy, 2003, 65, 21-35.	3.0	55
21	Risk adjustment and risk selection on the sickness fund insurance market in five European countries. Health Policy, 2003, 65, 75-98.	3.0	113
22	Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut, 2003, 52, 425-432.	12.1	180
23	Free choice of sickness funds in regulated competition: evidence from Germany and The Netherlands. Health Policy, 2002, 60, 235-254.	3.0	59